8-K
filed June 9, 2023, 7:59 PM ET
ticker FNCHQ
CIK 0001733257
other
confidence high
sentiment neutral
materiality 0.55
Finch Therapeutics shareholders approve 1-for-30 reverse stock split; elect two directors
Finch Therapeutics Group, Inc.
- Reverse stock split at 1-for-30 ratio approved by 40,212,819 votes for, 717,495 against.
- Common stock to begin trading on post-split basis on June 12, 2023 under new CUSIP 31773D200.
- Susan Graf and Chris Shumway elected as Class II directors through 2026; Graf 26,097,717 votes for, Shumway 24,013,503.
- Annual meeting had 40,934,688 shares present (~85.02% of outstanding).
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Finch Therapeutics Group, Inc.: Reverse stock split of common stock at a ratio of 1-for-30 (effective 2023-06-09).
- Change
- charter amendment
- Effective
- 2023-06-09
Exact text from the filing
On June 9, 2023, Finch Therapeutics Group, Inc. (the “Company”) filed a Certificate of Amendment (the “Charter Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 (the “Common Stock”), at a ratio of 1-for-30.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Finch Therapeutics Group, Inc. shareholders approved Election of two nominees as Class II directors: Susan Graf and Chris Shumway at the 2023-06-08 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
To elect two nominees as Class II directors: Susan Graf and Chris Shumway, each to hold office until the Annual Meeting of Stockholders in 2026. Nominee Votes For Votes Withheld Broker Non-Votes Susan Graf 26,097,717 4,226,794 10,610,177 Chris Shumway 24,013,503 6,311,008 10,610,177
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Finch Therapeutics Group, Inc. shareholders approved To approve the Charter Amendment to effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio of 1-for-30. at the 2023-06-08 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
To approve the Charter Amendment to effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio of 1-for-30. Votes For Votes Against Abstentions Broker Non-Votes 40,212,819 717,495 4,374 0
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.